信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01801 信达生物

未开盘 07-29 16:08:21

89.700

-0.200

-0.22%

最高91.850	最低88.150	成交量774.39万
今开90.550	昨收89.900	日振幅4.12%
总市值1,562亿	流通市值1,562亿	总股本17.41亿
成交额6.92亿	换手率0.44%	流通股本17.41亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":89.7,"timestamp":1785312501002,"preClose":89.9,"halted":0,"volume":7743860,"delay":0,"changeRate":-0.0022246941045606546,"floatShares":1741000000,"shares":1741000000,"eps":0.5452529535458267,"marketStatus":"未开盘","change":-0.2,"latestTime":"07-29 16:08:21","open":90.55,"high":91.85,"low":88.15,"amount":691859486,"amplitude":0.041157,"askPrice":89.7,"askSize":10000,"bidPrice":89.65,"bidSize":7000,"shortable":3,"etf":0,"ttmEps":0.5452529535458267,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785375000000},"marketStatusCode":0,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":89.9,"openAndCloseTimeList":[[1785288600000,1785297600000],[1785301200000,1785312000000]],"volumeRatio":0.8115076888577032,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.5554,"impliedVolPercentile":0.6531},"requestUrl":"/m/hq/s/01801/wiki","defaultTab":"wiki","newsList":[{"id":"2655832649","title":"【券商聚焦】国泰海通证券：全球多肽CDMO进入产能扩张周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2655832649","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655832649?lang=zh_cn&edition=full","pubTime":"2026-07-29 09:21","pubTimestamp":1785288070,"startTime":"0","endTime":"0","summary":"国内外的多肽CDMO公司均加大对于产能的投资建设，尤其注重从临床前到商业化生产的一站式服务能力建设。2026年4月，凯莱英医药与天津经开区管委会签署合作备忘录，在天津经开区持续扩建化学大分子创新药CDMO研发生产基地，预计投资规模达20亿元人民币。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986985","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURE","BK1564","01801","01177","LU1328277881.USD","LU1719994722.HKD","HK0000165453.HKD","LU0634319403.HKD","LU2242644610.SGD","IE00B5MMRT66.SGD","01877","LU1720050803.USD","06185","06160","LU0052750758.USD","LU0979878070.USD","LU0359202008.SGD","LU0051755006.USD","LU0417516738.SGD","BK1141","BK1588","09995","02616","IE00B0JY6N72.USD","BK1574","SG9999002463.SGD","LU1008478684.HKD","02611","IE00B543WZ88.USD","02142","601211","LU2476274308.USD","LU0307460666.USD","LU0561508036.HKD","BK1147","LU0181495838.USD","CDMO","161027","01093","LU0588546209.SGD","LU1251922891.USD","BK1583","02269","LU0348784397.USD","09688","09926","BK1610","LU0067412154.USD","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654458022","title":"【券商聚焦】交银国际：下半年医药板块有望迎来修复 但内部分化或持续加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2654458022","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654458022?lang=zh_cn&edition=full","pubTime":"2026-07-28 10:01","pubTimestamp":1785204072,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，近一个月恒生医疗保健指数涨17.4%，跑赢大市。其中，生物药、CXO及处方药板块表现较优于其他板块。机构持仓方面，2026年年中以来，内资持仓延续提升态势，而外资则略有降低。该机构指，中报季临近，7月以来多家公司业绩预告陆续发布，CXO板块表现亮眼，业绩和订单延续高增长态势。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986903","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276","06996","LU0856984785.SGD","06990","03329","09926","LU0572944931.SGD","02096","02269","01801","LU2476274308.USD","LU2399975544.HKD","LU1880383366.USD","01177","03692","09996","LU1813983027.USD","159938","01951","01548","LU2097828714.EUR","02162","09939","KCE","02273","HK0000320223.HKD","BK1219","LU2328871848.SGD","BK1587","LU0417516571.SGD","09966","01530","00013","06160","KURE","LU0634319403.HKD","LU2039709279.SGD","03759","01093","BK1521","LU0588546209.SGD","06078","HK0000165453.HKD","LU0196878994.USD","LU0348783233.USD","LU1720050803.USD","02268","02596","01952","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654453069","title":"“肥胖专病－医疗机构标准化体重综合管理服务体系建设项目”启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2654453069","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654453069?lang=zh_cn&edition=full","pubTime":"2026-07-26 20:32","pubTimestamp":1785069120,"startTime":"0","endTime":"0","summary":"本报讯 7月26日，由内分泌代谢科肥胖诊疗联盟牵头的“肥胖专病-医疗机构标准化体重综合管理服务体系建设项目”在南京正式启动。据了解，此次标准化体重综合管理服务体系建设以4个方面为主要抓手：在加强临床专科建设方面，将以肥胖专病为切入点，推动内分泌代谢科特色亚专业建设，打造差异化专科服务能力。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-07-26/doc-inikcymz0284073.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-07-26/doc-inikcymz0284073.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","LU2097828557.USD","LU2242644610.SGD","LU0455707207.USD","01801","LU2488822045.USD","LU2097828631.EUR","LU2097828805.USD","LU2097828714.EUR","LU0502904849.HKD","LU2328871848.SGD","HK0000165453.HKD","LU2097828474.EUR","BK1589","KURE","LU1969619763.USD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653484527","title":"招银国际：内地创新药板块估值修复将持续 首推信达生物(01801.HK)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2653484527","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653484527?lang=zh_cn&edition=full","pubTime":"2026-07-23 16:36","pubTimestamp":1784795818,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0502904849.HKD","LU1969619763.USD","LU2488822045.USD","BK1161","BK1589","LU2097828805.USD","LU0455707207.USD","KURE","LU2242644610.SGD","LU2328871848.SGD","06978","LU2097828714.EUR","LU2097828631.EUR","HK0000165453.HKD","BK1574","LU2097828557.USD","BK1583","01801","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653716228","title":"大行评级｜招银国际：创新药行业的基本面强劲，首推三生制药、信达生物等","url":"https://stock-news.laohu8.com/highlight/detail?id=2653716228","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653716228?lang=zh_cn&edition=full","pubTime":"2026-07-23 13:39","pubTimestamp":1784785161,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1161","LU0455707207.USD","01801","LU2097828474.EUR","KURE","LU1969619763.USD","LU2328871848.SGD","BK1593","LU2097828557.USD","LU2097828631.EUR","LU2488822045.USD","BK1589","BK1583","HK0000165453.HKD","LU0502904849.HKD","LU2242644610.SGD","LU2097828805.USD","LU2097828714.EUR","06978","BK1574","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653791754","title":"信达生物全球首款口服周制剂小分子GLP-1申报临床；药康生物2026年上半年净利润预增46.67%至60.78%｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2653791754","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653791754?lang=zh_cn&edition=full","pubTime":"2026-07-23 07:02","pubTimestamp":1784761351,"startTime":"0","endTime":"0","summary":"｜2026年7月23日星期四｜NO.1信达生物：全球首款口服周制剂小分子GLP-1申报临床7月21日，信达生物IBI3042的临床试验申请获国家药监局受理。今年6月，公司已在美国糖尿病学会（ADA）年会上披露了包括IBI3042在内的多项代谢管线数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607233817817194.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607233817817194.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GLP","JDOC","01801","159938","09939","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652269822","title":"创新药板块活跃 荣昌生物(09995)涨7.28% 多支头部公募大举举牌港股创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2652269822","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652269822?lang=zh_cn&edition=full","pubTime":"2026-07-20 10:26","pubTimestamp":1784514372,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药板块活跃，荣昌生物 涨7.28%，歌礼制药-B涨6.81%，科伦博泰生物涨6.70%，康诺亚-B涨6.25%，康方生物涨5.83%，药明合联涨5.53%，石药集团涨4.94%，三生制药涨5.02%，信达生物涨4.55%，药明生物涨4.60%，恒瑞医药涨4.00%，百济神州涨3.88%。头部机构密集触及举牌线，凸显对创新药板块的看好。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986240","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268","LU1242518931.SGD","LU0043850808.USD","LU0708995583.HKD","09926","LU0979878070.USD","KCAI","06160","LU0348735423.USD","LU0417516738.SGD","LU1242518857.USD","LU0516422440.USD","BK1588","HK0000165453.HKD","01672","KURE","BK1576","IE00BZ08YT58.USD","LU0327786744.USD","BK0239","LU2097828474.EUR","02162","LU0516423174.USD","LU0052750758.USD","159992","IBBQ","BK1593","LU0359201612.USD","01276","01801","06990","LU1951186391.HKD","LU1226288170.HKD","LU2399975544.HKD","VXUS","MEDX","LU2328871848.SGD","01093","09995","02269","LU1064130708.USD","LU0348827113.USD","688331","01530","LU0516422366.SGD","BK4585","LU0196878994.USD","LU1720050803.USD","SG9999002463.SGD","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134880917","title":"异动解读｜信达生物盘中上涨3.04%，生物科技板块集体回暖叠加BD交易催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1134880917","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134880917?lang=zh_cn&edition=full","pubTime":"2026-07-20 09:47","pubTimestamp":1784512055,"startTime":"0","endTime":"0","summary":"7月20日，信达生物盘中上涨3.04%，报93.05港元/股，成交额2.29亿港元。消息面上，公司近期宣布将IBI355大中华区以外权益授权予Spero Therapeutics，交易总额达11亿美元，里昂随后上调目标价至139.9港元并维持\"跑赢大市\"评级；野村、美银亦先后上调目标价。此外，生物科技板块今日集体走强，荣昌生物涨7.48%，科伦博泰生物涨6.81%，康方生物涨4.7%，百济神州涨4.2%，三生制药涨4.15%，板块前期回调后迎来资金回流。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106457065","title":"异动解读｜信达生物盘中下跌3.45%，报89.85港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1106457065","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106457065?lang=zh_cn&edition=full","pubTime":"2026-07-17 10:28","pubTimestamp":1784255333,"startTime":"0","endTime":"0","summary":"7月17日，信达生物盘中下跌3.45%，报89.85港元/股，成交额4.92亿港元。信达生物所在的生物科技行业中，个股整体表现偏弱，其中康方生物跌10.51%，三生制药跌10.16%，科伦博泰生物跌5.26%，百济神州跌2.46%，荣昌生物跌8.88%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651341039","title":"创新药连续大涨，这次真的不一样了吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2651341039","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651341039?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:05","pubTimestamp":1784192720,"startTime":"0","endTime":"0","summary":"政策上，医保初审通过率创新高，定价机制优化，并建立“医保+商保”双层支付体系；产业上，上半年BD交易总额达1100亿美元，国际竞争力显著提升；资金面上，内外资持续回流。行业正从“讲故事”转向盈利兑现，国金证券认为，2027年有望成为中国创新药海外商业化集中兑现的重要节点。","market":"hk","thumbnail":"https://static.tigerbbs.com/8daedf52c02cecfd417dcbd813afb3fa","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8daedf52c02cecfd417dcbd813afb3fa"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3777107","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622","159992","MEDX","09688","02268","03759","BK1161","09606","02137","03347","09966","02269","06978","BK1574","IBBQ","01672","00241","06606","09995","06996","02359","06618","01801"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2651419582","title":"里昂：升信达生物(01801)目标价至139.9港元 海外再有交易合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2651419582","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651419582?lang=zh_cn&edition=full","pubTime":"2026-07-16 14:23","pubTimestamp":1784183031,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，信达生物(01801)于7月14日宣布，已将其免疫学药物IBI355在大中华区以外的权益授权予Spero Therapeutics，交易总额达11亿美元。该行相信，尽管此次交易规模小于今年初达成的另外两笔交易，但最新交易再次良好地反映了信达生物的研发实力。里昂将信达生物目标价由135.8港元上调至139.9港元，维持“跑赢大市”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651164084","title":"大行评级｜里昂：上调信达生物目标价至139.9港元，维持“跑赢大市”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2651164084","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651164084?lang=zh_cn&edition=full","pubTime":"2026-07-16 14:11","pubTimestamp":1784182307,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1583","HK0000165453.HKD","BK1161","LU2097828631.EUR","LU2097828805.USD","LU2097828474.EUR","BK1589","LU0455707207.USD","LU2242644610.SGD","LU0502904849.HKD","KURE","01801","LU2097828714.EUR","LU2328871848.SGD","LU2488822045.USD","LU2097828557.USD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146748938","title":"异动解读｜信达生物盘中下跌3.09%，报94.05港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1146748938","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146748938?lang=zh_cn&edition=full","pubTime":"2026-07-16 10:15","pubTimestamp":1784168132,"startTime":"0","endTime":"0","summary":"7月16日，信达生物盘中下跌3.09%，报94.05港元/股，成交额7.7亿港元。信达生物所在的生物科技行业中，个股整体表现偏弱，其中百济神州跌0.48%，康方生物跌1.55%，三生制药跌1.43%，科伦博泰生物跌3.63%，映恩生物-B涨0.76%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651810439","title":"港股早盘高开高走 恒指半日涨1.46% 创新药、猪肉概念强势","url":"https://stock-news.laohu8.com/highlight/detail?id=2651810439","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651810439?lang=zh_cn&edition=full","pubTime":"2026-07-15 12:11","pubTimestamp":1784088667,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股早盘高开高走，三大股指均升逾1%。截至午间收盘，恒生指数上涨1.46%；国企指数涨1.16%；恒生科技指数涨1.39%。猪价底部大概率已现，预计周期临近上行。预计2026年半年度归属于上市公司股东的扣除非经常性损益的净利润约为人民币20.00亿元到人民币26.00亿元，与上年同期相比，将增加人民币18.62亿元到人民币24.62亿元，同比增长1349%到1784%。MiniMax盘中反复拉升，午间收涨14.96%。港股将受益于中国内地强劲而有韧性的经济表现，建议超配H股。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/YWY0NWM4YTUxZGFlZmZjNmE5MDYxNjI4NjU1Mjc3NzM1Mzg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YWY0NWM4YTUxZGFlZmZjNmE5MDYxNjI4NjU1Mjc3NzM1Mzg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985921","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1523","LU0251144936.SGD","LU0588546209.SGD","LU1808992512.USD","SG9999002562.SGD","LU0463099449.HKD","BK1550","83115","LU0828237940.HKD","LU0862451753.SGD","02714","LU0405327494.USD","LU0348766576.USD","BK1549","BK1562","IE0008369823.USD","LU0862451837.USD","LU3063872942.SGD","HSTECH","00857","LU0516422952.EUR","01477","LU0417516902.SGD","LU0821914370.USD","LU1813983027.USD","LU2399975544.HKD","LU1048588211.SGD","BK1226","LU1226287792.SGD","BK1528","03115","LU2476274308.USD","BK1515","LU2045819591.USD","IE00B031HY20.USD","01610","LU1008478684.HKD","LU2097828805.USD","LU0348735423.USD","SGXZ86797644.SGD","SG9999001226.SGD","WXXWY","LU1226287529.USD","LU1880383366.USD","SG9999012744.USD","06869","MCHmain","LU0880133367.SGD","IE00BWDBJ730.SGD","LU1785774172.SGD","LU0359202008.SGD","LU0455707207.USD","LU0163747925.USD","LU0348767384.USD","LU1051769294.HKD","LU1226288170.HKD","BK1589","LU0315178854.USD","LU1303224171.USD","LU0173614495.USD","LU0588545490.SGD","LU1497733631.SGD","LU0890818403.SGD","LU1522347837.USD","LU0228367735.SGD","03037","BK1610","LU1831875114.USD","LU0051755006.USD","LU0348805143.USD","LU1960683339.HKD","SG9999001093.SGD","LU0634319403.HKD","LU0823426308.USD","LU0417516571.SGD","LU0651946864.USD","BK1584","LU0043850808.USD","LU0865486749.SGD","IE0008368742.USD","BK1521","LU1515016050.SGD","BK1603","LU0320764599.SGD","LU1224444064.USD","BK1607","BK1191","BK1161","LU0348825331.USD","KURE","LU1046422090.SGD","IE00B5MMRT66.SGD","LU0588545730.USD","LU0359201885.HKD","IE00B543WZ88.USD","LU2039709279.SGD","LU1051768304.USD","BK1574","LU0348783662.USD","BK1614","LU0244354667.USD","LU0441854154.USD","LU0708995583.HKD","SG9999002463.SGD","IE00BPRC5H50.USD","LU0456846285.SGD","LU1770034418.SGD","SG9999003461.SGD","HK0000286598.CNH","LU2257852520.SGD","LU1720050803.USD","LU0169518387.USD","LU0501845795.SGD","82800","LU0502904849.HKD","LU0588545904.SGD","LU0067412154.USD","LU0072913022.USD","601869","LU1794554557.SGD","09926","IE00BQJZWZ67.USD","LU1282651121.HKD","02359","02419","LU1807302812.USD","LU2097828714.EUR","07500","LU0871576103.HKD","LU1242518857.USD","LU0572944931.SGD","LU2097828474.EUR","LU0611395673.USD","LU1719994722.HKD","002714","LU1675838814.USD","IE00BZ08YR35.GBP","LU0456827905.SGD","LU1226288253.USD","603259","HK0000165453.HKD","LU0640798160.USD","09115","IE00BZ08YT58.USD","LU1634259557.SGD","LU2125910500.SGD","688981","LU1497734951.SGD","LU0675040207.SGD","07300","601628","BK1117","HSI","SCHYY","SGXZ62798434.SGD","LU0417516738.SGD","513600","LU1152091168.USD","01801","BK1506","LU0164865239.USD","00100","LU0315179316.USD","IE00B19Z5X02.USD","LU0819121731.USD","LU1115378108.SGD","LU0314109678.HKD","SBHMY","SG9999012736.USD","LU1188198961.HKD","LU0540923850.HKD","SG9999006597.SGD","LU0469268626.HKD","BK1141","LU0516422366.SGD","LU1211504680.USD","LU2778985437.USD","01177","07200","LU0140636845.USD","LU1242518931.SGD","SG9999004220.SGD","SG9999012728.SGD","02269","601857","LU0359201612.USD","LU0405327148.USD","LU0052750758.USD","LU1634259391.SGD","LU0516423174.USD","BK1172","01928","LU0516423091.SGD","LU0326950275.SGD","LU2097828631.EUR","BK1184","BK1149","LU1023057109.AUD","BK1163","BK1237","BK1583","02833","LU1226287875.USD","LU1251922891.USD","LU2097828557.USD","LU0348827113.USD","LU0516422440.USD","LU2488822045.USD","IE00B0JY6N72.USD","LU0972618739.USD","LU0348784397.USD","LU0561508036.HKD","LU2293587155.HKD","LU0856984785.SGD","LU0307460666.USD","LU2476274720.SGD","LU1961090484.USD","LU0039217434.USD","00981","02268","00386","LU0651947912.USD","LU1328277881.USD","02628","LU0531971595.HKD","LU0823426480.USD","02800","IE0032431581.USD","LU0327786744.USD","LU2242644610.SGD","LU0211977185.USD","01093","LU1048596156.SGD","600028","LU1969619763.USD","LU1993786604.SGD","03419","LU1497733557.USD","SG9999012710.SGD","SG9999014674.SGD","LU0181495838.USD","LU2328871848.SGD","BK1526","IE00BZ08YS42.EUR","LU0293314216.USD","LU1951186391.HKD","LU0048597586.USD","LU0348783233.USD","06990","LU1688375341.USD","LU0979878070.USD","HHImain","BK1576","LU0072462343.USD","LU1152091754.HKD","LU0196878994.USD","LU0287142896.SGD","LU1282651048.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651291435","title":"创新药概念全线扬升 科伦博泰生物(06990)涨逾11% 机构指创新药企迎业绩兑现窗口","url":"https://stock-news.laohu8.com/highlight/detail?id=2651291435","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651291435?lang=zh_cn&edition=full","pubTime":"2026-07-15 11:07","pubTimestamp":1784084836,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念盘中全线扬升，截至发稿，欧康维视生物-B 涨13.35%，科伦博泰生物涨11.20%，康方生物涨8.82%，信达生物涨8.72%，三生制药涨8.11%，康诺亚-B涨7.62%，药明合联涨7.52%，荣昌生物涨7.09%，乐普生物涨6.87%，亚盛医药涨6.26%。该机构持续看好国内创新药出海β向上可持续性，提示投资者关注2027年起众多前期已达成BD的分子将在海外开启商业化新周期所带来的投资机会。","market":"fut","thumbnail":"https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985914","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720050803.USD","LU2097828714.EUR","06855","01477","09926","IE00BPRC5H50.USD","02157","LU2488822045.USD","02162","BK1589","159992","LU2097828805.USD","MEDX","BK1141","LU0417516571.SGD","SG9999014674.SGD","IE00B543WZ88.USD","BK1593","LU0348825331.USD","LU0561508036.HKD","LU0540923850.HKD","KURE","LU0348784397.USD","06990","LU0348827113.USD","LU0502904849.HKD","LU1961090484.USD","LU0634319403.HKD","BK1574","LU2399975544.HKD","LU2778985437.USD","BK1587","LU2097828474.EUR","BK1191","06978","01530","LU2476274308.USD","BK1161","LU0417516902.SGD","09995","LU0348767384.USD","LU2328871848.SGD","01801","LU0417516738.SGD","LU2097828631.EUR","LU2097828557.USD","BK1583","IBBQ","02268","LU0455707207.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110317463","title":"异动解读｜信达生物盘中上涨3.78%，与Spero Therapeutics就第三代抗CD40L抗体达成独家授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1110317463","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110317463?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:38","pubTimestamp":1784079498,"startTime":"0","endTime":"0","summary":"7月15日，信达生物盘中上涨3.78%，报94.35港元，成交额3.33亿港元。消息面上，信达生物于7月14日宣布与Spero Therapeutics就IBI355达成独家授权协议。IBI355是一款已准备进入二期临床试验阶段的第三代抗CD40L单抗，Spero计划于明年二季度启动IBI355治疗IgG4相关疾病的II期研究，信达生物计划于明年初前在中国启动IBI355治疗干燥综合征的II期研究。此前，公司还先后与礼来达成Verzenios中国大陆商业化协议、与辉瑞开展合作，多家券商维持\"买入\"评级，目标价区间在119.2至134.5港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651384024","title":"港股异动 | 信达生物(01801)涨超3% 与Spero就IBI355达成独家许可协议 将于明年初启动治疗SjD临床II期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2651384024","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651384024?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:35","pubTimestamp":1784079328,"startTime":"0","endTime":"0","summary":"信达生物(01801)涨超3%，截至发稿，涨3.28%，报93港元，成交额1.01亿港元。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260715/20260715093749_87050.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260715/20260715093749_87050.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467631.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU2097828557.USD","BK1161","LU2328871848.SGD","KCAI","LU2097828474.EUR","LU2097828631.EUR","KURE","BK4585","LU2097828714.EUR","BK1589","LU2488822045.USD","HK0000165453.HKD","LU1969619763.USD","BK1583","BK4588","LU0502904849.HKD","01801","LU0455707207.USD","LU2097828805.USD","LU2242644610.SGD","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651387224","title":"港股开盘向好 恒指高开0.87% 中国人寿(02628)涨4.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651387224","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651387224?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:33","pubTimestamp":1784079222,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股开盘向好，恒指高开0.87%，国企指数高开0.61%，恒生科技指数高开0.78%。长飞光纤光缆高开14.94%，公司发盈喜，预期截至2026年6月30日止6个月录得归属于公司股东的净利润24亿至30亿元人民币(下同)，较去年同期增长711%至914%。天齐锂业高开3.75%，公司公布，预期截至2026年6月30日止六个月归属于公司股东的净利润介乎28.5亿至42.5亿元人民币(下同)，去年同期净利润约8441万元。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/NzMyOTI2MTc2NzYxOTM1NTM3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NzMyOTI2MTc2NzYxOTM1NTM3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985889","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1323998911.USD","LU0117844026.USD","02269","LU2028103732.USD","LU2097828474.EUR","LU2449936058.SGD","LU0472753341.HKD","07300","LU0315178854.USD","LU0348816934.USD","LU0577902611.USD","LU0348788117.USD","LU0593848301.USD","LU1808992512.USD","LU0175139822.USD","LU0543330566.HKD","LU0955648018.USD","IE00BD6J9T35.USD","BYDDY","LU0877626530.USD","SG9999004303.SGD","SG9999004220.SGD","IE00B031J352.USD","SG9999012710.SGD","SG9999001226.SGD","LU1655091459.SGD","BK1521","LU0289960550.SGD","LU0607220059.USD","HK0000306685.HKD","LU0211977185.USD","LU1983260115.SGD","LU0029874905.USD","LU0862451753.SGD","LU0072462343.USD","FDRV","HSI","02800","LU0588545904.SGD","SG9999015986.USD","LU0955669360.SGD","IE00BKZH1Z71.USD","BK1584","LU0106259558.USD","SG9999015978.USD","SG9999014039.USD","LU2242644610.SGD","SG9999015952.SGD","SG9999001903.USD","BK1149","LU0873338254.USD","LU1861214812.USD","LU1868838027.USD","LU1956131251.USD","01211","BK1523","LU0149534421.HKD","LU1105468828.SGD","LU1242518931.SGD","LU0417516738.SGD","BK1526","LU0862451837.USD","LU1328277881.USD","LU0049112450.USD","601628","LU0572940350.SGD","LU0370786039.SGD","LU1044874839.SGD","LU0345776255.USD","LU0456846285.SGD","TCHI","LU1363072403.SGD","LU0955623706.USD","SG9999006597.SGD","LNVGY","AAGIY","LU0348814723.USD","BK1561","IE00BZ08YS42.EUR","002466","LU0588545730.USD","LU0588545490.SGD","SG9999012728.SGD","CSUAY","IE0003795394.USD","LU1880383440.USD","LU0918141887.USD","01801","LU2357125470.USD","LU0348825331.USD","LU2153591404.USD","LU1831875114.USD","LU0057025933.USD","IE00BFXG0V08.USD","LU0235996351.USD","LU2089283258.USD","LU0164880469.USD","LU1242518857.USD","82800","LU0244354667.USD","LU0594300179.USD","LU0307460666.USD","HK0000320264.USD","00992","LU0072913022.USD","LU1629966141.USD","IE00BZ08YR35.GBP","LU1303224171.USD","IE00BF5LJ272.USD","LU1642822792.SGD","LU0061477393.USD","LU0228367735.SGD","LU0918141705.HKD","LU1102505929.USD","LU1981816686.USD","LU0214875030.USD","LU1719994722.HKD","LU2328871848.SGD","LU0082770016.SGD","LU2089284900.SGD","BK1116","IE00B0169L03.USD","LU0463099449.HKD","BK1550","LU1048484197.HKD","LU0196878994.USD","LU0345775950.USD","LU0132412106.USD","LU0048388663.USD","LU2152927971.USD","LU0048575426.USD","LU0505663152.USD","BK1129","LU1770036033.HKD","LU1880383366.USD","LU2265009873.SGD","LU0605514214.HKD","BK1161","LU0396098781.USD","IE00B067MR52.USD","LU0831093199.SGD","LU0511384066.AUD","BK1539","LU1400636574.HKD","LU0348827113.USD","LU0738912210.USD","LU1048596156.SGD","LU1235295612.USD","LU0577902371.SGD","LU1439103000.SGD","NNFSF","81211","IE0008368742.USD","LU0096374516.USD","IE0003851619.USD","HHImain","SMOG","LU2294711713.HKD","LU0557290698.USD","LU0149721374.USD","LU0289961442.SGD","LU0577902538.SGD","LU0048580855.USD","LU0359201612.USD","LU0169518387.USD","LU0577902298.EUR","LU0650527681.SGD","LU1251922891.USD","LU1267930227.SGD","IE0032834883.USD","LU0878005551.USD","LU1044876610.USD","LU0106252389.USD","SG9999002828.SGD","03419","LU2097828557.USD","LU0128522744.USD","LU1481107354.HKD","LU0414403682.SGD","LU2488822045.USD","LU0831103253.SGD","LU1048588211.SGD","LU1734074674.USD","LU0052750758.USD","LU0029875118.USD","07200","LU0011963245.USD","BBAX","EPP","LU0188438112.USD","81299","300750","LU0541501648.USD","LU0266013472.USD","LU1130305938.SGD","LU0762542818.HKD","LU0541502299.USD","LU0181495838.USD","BK1582","LU0985320562.USD","IE00B031HW06.USD","BK1123","LU1504937902.USD","LU2097828805.USD","GB00BDT5M118.USD","SGXZ23171101.USD","LU0791591158.USD","LU0310800965.SGD","LU1400636657.SGD","LU0067412154.USD","LU0762541174.USD","LU1645745479.HKD","LU0320764755.SGD","LU1688375341.USD","LU2249611893.SGD","BK1258","HK0000306701.USD","LU0797268264.HKD","LU0165289439.USD","LU1993786604.SGD","LU0158827781.USD","LU0819123356.HKD","BK1178","LU0417516902.SGD","LU0630378692.HKD","BK1505","LU0441854154.USD","LU2476274720.SGD","HYDD.SI","LU0819121731.USD","LU1720050803.USD","IE0008368411.USD","LU0516422440.USD","LU0823039010.USD","LU0828238088.HKD","LU0197773673.USD","LU0823397285.USD","02628","LU0620787316.HKD","LU0823414478.USD","BK1594","LU0516422366.SGD","IE0031814852.USD","LU0287142896.SGD","LU1046422090.SGD","07500","01088","LU0359201885.HKD","LU1623119135.USD","LU0326948709.USD","BK1610","LU0791590937.USD","LU1008478684.HKD","LU0577902454.USD","LU1152091168.USD","LU2111349929.HKD","LU1969619763.USD","SG9999000327.SGD","LU2023251221.USD","IE00B0JY6N72.USD","LU0054450605.USD","LU1868837722.USD","01209","LU0828237510.HKD","SG9999002463.SGD","LU0456842615.SGD","LU0594300419.USD","LU0264606111.USD","002594","LU1044875133.USD","LU0210527791.USD","IE0004091025.USD","IE0004086264.USD","LU0254981946.USD","LU0143863784.USD","SG9999014674.SGD","03115","MCHmain","LU0672654166.SGD","LU1568876251.USD","BK1193","LU0259732245.USD","LU0289739343.SGD","HK0000320223.HKD","IE00B8L5B284.USD","LU1961090484.USD","SG9999001846.SGD","80992","LU2097828714.EUR","LU0251143458.SGD","LU1282648689.USD","06869","LU1868837565.USD","SG9999006514.SGD","IE00BZ08YT58.USD","BK1509","LU0158827948.USD","LU0069063385.USD","LU0634319403.HKD","LU0348735423.USD","IE00B3T34201.USD","LU1813983027.USD","LU0823397103.USD","LU0502904849.HKD","BK1607","LU0823414551.USD","HK0000165453.HKD","LU0197773160.USD","LU2125910500.SGD","03750","LU2097828631.EUR","IE00B5TLWC47.USD","LU0823426480.USD","SG9999001689.USD","SG9999012744.USD","LU2271345857.HKD","LU0543330483.HKD","LU0784639295.USD","BK1200","BK1514","LU1202635105.USD","IE0008369823.USD","LU2153592121.USD","LU1568876335.HKD","LU0823038988.USD","LU1770034418.SGD","LU2008162690.USD","LU0192582467.USD","LU0140636845.USD","LU1804176565.USD","IE0032431581.USD","LU2476274308.USD","LU0229945570.USD","LU0865486749.SGD","IE0009570106.USD","09115","LU0359202008.SGD","LU1670756490.USD","LU2087589342.USD","LU2506951792.HKD","LU0314109678.HKD","LU0531971595.HKD","LU0052756011.USD","LU0054237671.USD","LU0611395673.USD","LU0039217434.USD","LU0708995153.HKD","LU0856984785.SGD","LU0164939612.USD","LU1152091754.HKD","LU0043850808.USD","LU1196710864.SGD","IE00BYQQ9H92.USD","LU0164872284.USD","LU0455707207.USD","LU0708995583.HKD","LU0048597586.USD","LU0084288322.USD","LU1102505762.USD","601869","LU2360107325.USD","LU3063872942.SGD","LU0971096721.USD","09633","BK1506","LU1366334578.USD","IE00B8HQ1Z84.USD","LU1481012133.USD","BK1583","83115","601088","LU1119993845.HKD","LU0821914370.USD","LU2257852520.SGD","LU0049853897.USD","LU0516423091.SGD","LU0051755006.USD","LU0128522157.USD","LU1366334651.USD","IE00B031HY20.USD","BK1184","LU0320764243.SGD","SG9999002562.SGD","LU0327786744.USD","LU2177674079.SGD","BK1229","LU0531970944.HKD","LU2045819591.USD","LU0828237940.HKD","SG9999014021.USD","02833","LU0082770016.USD","LU0164865239.USD","LU0890818403.SGD","LU0516422952.EUR","LU0675040207.SGD","HK0000286598.CNH","LU1328615791.USD","01299","LU1712237335.SGD","LU0501845795.SGD","LU0762540952.USD","LU0882747503.HKD","SG9999015945.SGD","03037","LU0143863198.USD","LU0320764599.SGD","LU0509642566.USD","LU1861219969.SGD","LU0348805143.USD","LU0205439572.USD","HK0000151867.HKD","09696","LU1439102457.SGD","WXXWY","LU0128525689.USD","LU1023057109.AUD","LU2348774022.SGD","BK1589","LU0572944931.SGD","00753","LU1807302812.USD","LU2039709279.SGD","LU0630378429.USD","SG9999012736.USD","LU0449515922.USD","LU0269904917.USD","LU0516423174.USD","LU0326950275.SGD","LU0898667661.SGD","BK1119","601111","LU0880133367.SGD","SG9999014005.SGD","SG9999014013.SGD","LU0163747925.USD","LU0979878070.USD","LU0588546209.SGD","BK1576","LU0449509016.USD","BK1141","LU1400636491.USD","LU0228659784.USD","LU2399975544.HKD","BK1540","LU2226246903.HKD","LU0823426308.USD","LU1821325948.USD","LU1794554557.SGD","SG9999000459.SGD","IE00B97KM107.HKD","BK1522","LU0173614495.USD","LU1188198961.HKD","BK1538","LU0456827905.SGD","LU2778985437.USD","LU0469268626.HKD","LU0886674414.USD","LU1960683339.HKD","HK0000288743.USD","LU0540923850.HKD","KURE","LU0878004406.USD","LU0261950470.USD","LU0261950983.USD","LU0572939691.SGD","IE0034224299.USD","LU0871576103.HKD","LU0261947096.USD","LU0561508036.HKD","HK0000288784.HKD","513600","BK1542","LU2348773727.SGD","LU0251144936.SGD","HSTECH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130460477","title":"Spero与信达生物合作，将于2027年初在中国启动干燥综合征二期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1130460477","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130460477?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:02","pubTimestamp":1784023345,"startTime":"0","endTime":"0","summary":"斯佩罗治疗公司与信达生物宣布，双方将合作推进一项针对干燥综合征的创新疗法临床研究。根据最新规划，该疗法的二期临床试验预计于2027年初在中国正式启动。此次合作结合了斯佩罗治疗公司在感染性疾病与炎症领域的技术积累，以及信达生物在中国市场的临床开发与商业化优势。若试验进展顺利，该药物有望为中国的干燥综合征患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0455707207.USD","LU0502904849.HKD","01801","LU2097828631.EUR","SPRO","KURE","BK1161","LU2097828557.USD","LU2488822045.USD","LU2242644610.SGD","BK1589","LU2097828714.EUR","LU2097828805.USD","BK1583","LU2097828474.EUR","HK0000165453.HKD","LU2328871848.SGD","BK4139","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159666906","title":"信达生物与Spero Therapeutics就Ibi355 (SP001)达成独家授权协议，该第三代抗CD40L抗体已准备进入二期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=1159666906","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159666906?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:01","pubTimestamp":1784023292,"startTime":"0","endTime":"0","summary":"信达生物与Spero Therapeutics Inc.共同宣布，双方已就Ibi355（亦称为SP001）达成一项独家授权协议。该候选药物是一款已准备进入二期临床试验阶段的第三代抗CD40L抗体。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828714.EUR","01801","LU1969619763.USD","HK0000165453.HKD","LU2097828474.EUR","LU2097828631.EUR","SPRO","BK1589","LU0502904849.HKD","KURE","LU2097828557.USD","LU2328871848.SGD","BK4139","BK1583","LU2488822045.USD","BK1161","LU2097828805.USD","LU2242644610.SGD","LU0455707207.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":-0.0276},{"period":"1month","weight":0.1205},{"period":"3month","weight":-0.0033},{"period":"6month","weight":0.106},{"period":"1year","weight":-0.1026},{"period":"ytd","weight":0.1764}],"compareEarnings":[{"period":"1week","weight":0.0368},{"period":"1month","weight":0.1208},{"period":"3month","weight":0.0012},{"period":"6month","weight":-0.0577},{"period":"1year","weight":0.0111},{"period":"ytd","weight":0.0069}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事研发、生产及销售治疗肿瘤、心血管及代谢（CVM）、自身免疫及眼科等重大疾病创新药物的投资控股公司。药物形式包括单克隆抗体、多特异性抗体、免疫细胞因子、抗体偶联药物（ADC）、细胞治疗及小分子药物等。该公司的主要产品包括达伯舒（信迪利单抗注射液）、达攸同（贝伐珠单抗注射液）、苏立信（阿达木单抗注射液）、达伯华（利妥昔单抗注射液）、达伯坦（佩米替尼片）等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.041076},{"month":2,"riseRate":0.75,"avgChangeRate":0.110526},{"month":3,"riseRate":0.25,"avgChangeRate":-0.01934},{"month":4,"riseRate":0.75,"avgChangeRate":0.043223},{"month":5,"riseRate":0.375,"avgChangeRate":0.014737},{"month":6,"riseRate":0.625,"avgChangeRate":0.116146},{"month":7,"riseRate":0.5,"avgChangeRate":0.024659},{"month":8,"riseRate":0.714286,"avgChangeRate":0.000214},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032182},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.02286},{"month":11,"riseRate":0.625,"avgChangeRate":0.079172},{"month":12,"riseRate":0.375,"avgChangeRate":0.024026}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}